|
|
Volumn 10, Issue 4, 2011, Pages 243-245
|
|
Landmark lupus approval opens door for next wave of drugs
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
A 623;
ABATACEPT;
AGS 009;
ALPHA INTERFERON KINOID;
AMG 557;
AMG 811;
ATACICEPT;
BELIMUMAB;
BENLYSTA;
BT 063;
CC 11050;
CC 930;
CDP 7657;
CNTO 136;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
EPRATUZUMAB;
FORIGERIMOD;
IMMUNOSUPPRESSIVE AGENT;
LAQUINIMOD;
LY 2127399;
MONOCLONAL ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PLACEBO;
PREDNISONE;
RITUXIMAB;
RONTALIZUMAB;
SBI 087;
SIFALIMUMAB;
STEROID;
UNCLASSIFIED DRUG;
ARTICLE;
B CELL LYMPHOMA;
CELL ACTIVATION;
CYTOKINE PRODUCTION;
DISEASE ACTIVITY;
DRUG APPROVAL;
DRUG BINDING;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG MARKETING;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG TARGETING;
FOOD AND DRUG ADMINISTRATION;
GENOMICS;
HEALTH STATUS;
HUMAN;
LOW DRUG DOSE;
NONHUMAN;
ORGANIZATION;
OUTCOME ASSESSMENT;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
RHEUMATOID ARTHRITIS;
SCORING SYSTEM;
SYSTEMIC LUPUS ERYTHEMATOSUS;
TREATMENT OUTCOME;
TREATMENT PLANNING;
VISUAL ANALOG SCALE;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
DRUG APPROVAL;
DRUG DESIGN;
DRUG DISCOVERY;
GENOMICS;
HUMANS;
LUPUS ERYTHEMATOSUS, SYSTEMIC;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79953326963
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3413 Document Type: Article |
|
Times cited : (6)
|
|
References (4)
|
